AI-based Measurements of Tumour Burden in PSMA PET-CT - Trial NCT06363435
Access comprehensive clinical trial information for NCT06363435 through Pure Global AI's free database. This phase not specified trial is sponsored by Elin Tragardh and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 1500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
Observational
device
Sponsor & Location
Elin Tragardh
Skane University Hospital
Timeline & Enrollment
N/A
Mar 29, 2024
Mar 01, 2033
Primary Outcome
Tumour burden (cm3) in relation to overall survival
Summary
The primary aim of the present study is to evaluate how automatically calculated (by an
 AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x
 SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as
 the total tumour burden predicts overall survival (OS) in patients with prostate cancer
 (newly diagnosed and patients with biochemical recurrence).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06363435
Device Trial